We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Akcea Therapeutics

News List

Pfizer Initiates Study of Vupanorsen americanpharmaceuticalreview
November 12, 2020
Ionis Pharmaceuticals and its wholly owned subsidiary Akcea Therapeutics announced Pfizer has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and ..
Akcea Therapeutics Appoints CMO contractpharma
July 10, 2020
William Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products.
Final NICE guidance issued for Akcea’s Tegsedi pharmatimes
May 28, 2019
Akcea Therapeutics UK has announced that the National Institute for Health and Care Excellence (NICE) has published a final guideline for its nerve damage drug, Tegsedi (inotersen).
Akcea lays off 10% of staff following volanesorsen rejection fiercebiotech
September 10, 2018
Akcea had built its headcount up to 270 in anticipation of bringing volanesorsen to market.